Exelixis Moves Into Metabolic Disease

genomeweb
360dx

Exelixis Moves Into Metabolic Disease

Jul 26, 2001

NEW YORK, July 26 – Exelixis is expanding its internal drug discovery efforts into metabolic diseases, including cardiovascular disease, diabetes, and obesity, the company said Thursday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Startup Cadex Genomics Raises $1.5M
In Brief This Week: BioDirection, OncoCyte, SpeeDx, and More
All Breast Cancer Patients Should Receive Multigene Panel Tests, Surgeon Group Says
Obesity-Related Gene Methylation Changes Connected to BMI in Healthy Adolescents
Jefferies Initiates Coverage of CareDx With Buy Rating
New Products Posted to GenomeWeb: Invitae, Promega, Myriad Genetics, More

The Scan

WHO Panel Announced

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

Research Reproducibility Scores

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

Tests for All Diagnosed

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

This Week in Science

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Main menu